EGFR and neoplasm: This large retrospective analysis that evaluated a homogeneous population of mCRC patients undergoing EGFR-based first-line chemotherapy demonstrated that patients with left-sided primary tumours experienced significantly better outcomes in terms of ORR and DPR.